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Introduction CLC-Ka and CLC-Kb chloride channels are expressed along the nephron from the thin ascending limb to the collecting duct where they are pivotal for chloride exit across the basolateral membrane (Uchida and Sasaki, 2005; Jentsch et al., 2002) . The significance of these channels for salt homeostasis is illustrated by genetic disorders (Jentsch et al., 2005) . Defects in the gene encoding CLC-Kb reduce activity producing Bartter's syndrome type III, a disease characterized by severe salt wasting and hypokalemia (Simon et al., 1997) . CLC-Kb is implicated in transepithelial NaCl transport in the thick ascending limb and collecting ducts, while CLC-Ka-mediated Cl -transport in the thin ascending limb constitutes a component of the countercurrent system of the inner medulla.
Its loss disrupts the entire system, as suggested by the nephrogenic diabetes insipidus phenotype of CLC-K1 knock-out mice (Akizuki et al., 2001 ).
CLC-K channels are also expressed in the inner ear where they are involved in endolymph secretion, a mechanism pivotal for sound signal transduction (Estévez et al., 2001) . Furthermore, for a correct expression and function, CLC-K channels require the presence of the barttin β subunit (Estévez et al., 2001; Waldegger et al., 2002) . Barttin produces an increase of CLC-K channel expression at the plasma membrane (Estévez et al., 2001; Waldegger et al., 2002) . Mutations in barttin cause type IV Bartter's syndrome, a disease characterized by renal failure accompanied by sensorineural deafness . In support of the hypothesis that defects in barttin MOL # 17384
Materials and Methods

Expression in Xenopus laevis oocytes and voltage-clamp analysis
WT CLC-Ka, CLC-Kb and their mutants, obtained as previously described (Picollo et al., 2004) , were co-expressed with the activating mutant Y98A of human barttin (Estévez et al., 2001 ).
Expression in oocytes and electrophysiological measurements were performed as previously described (Pusch et al., 2000) . Briefly, voltage-clamp data were acquired at room temperature (21-25°C) using the Pulse program (HEKA, Lambrecht, Germany) or a custom acquisition program (Gepulse) and a custom-built amplifier or a TEC03 amplifier (npi electronic, Tamm, Germany).
Currents were recorded in the standard solution containing (in mM) 90 NaCl, 10 CaCl 2 , 1 MgCl 2 , 10 HEPES at pH 7.3. In experiments with low extracellular [Ca 2+ ], 1.8 mM CaCl 2 was used and NaCl was increased to 106 mM to balance osmolarity and salt-strength.
Similar voltage-clamp pulse protocols for CLC-Ka and CLC-Kb, with a longer pulse duration for CLC-Kb, were used: from a holding potential of -30 mV, after a prepulse to 60 mV (or -100 mV)
for 100 or 200 ms (for CLC-Ka and CLC-Kb respectively), voltage was stepped from -140 to 80 mV in 20 mV increments for 200 or 500 ms (for CLC-Ka and CLC-Kb respectively), followed by a final tail pulse to -100 mV. To evaluate the on-set and wash-out of drug effects a pulse to 60 mV was applied every 2 s.
As a control, we routinely applied a solution containing 100 mM I -that blocks currents carried by MOL # 17384
NFA derivatives
The following drugs were purchased from Sigma-Aldrich (Milano-Italy): niflumic acid (NFA), flufenamic acid (FFA), mefenamic acid (MFA), meclofenamic acid (MCFA), tolfenamic acid (TFA), 2-(phenylamino)benzoic acid (DPC).
Remaining compounds were synthesized according to previously reported procedures: MT-4, MT-6
and MT-7 were prepared by condensation of 2-chloronicotinic acid with the appropriate substituted amines (Sherlock et al., 1988) . The phenoxypyridinecarboxylic acids (Li-3, Li-10, Li-6 and Li-11)
were synthesized condensing 2-chloronicotinic acid with the opportune sodium phenoxide using an excess of the phenol (Villani et al., 1975) . For Li15 the condensation was modified using equimolar quantities of the acid and the phenolate in DMF (Fujiwara and Kitagawa, 2000) . EB-168 was synthesized by treating commercially available NFA with an excess of boran methylsulfide complex in dry tetrahydrofuran.
Compounds were daily prepared in dimethylsulfoxide stock solutions and the final concentrations were obtained by appropriate dilution with the solution used for the electrophysiological recordings.
Modeling study
We searched the lowest energy conformers for each drug by a systematic MMFF (Merck Molecular Force Field) analysis neglecting solvent presence. A restricted number of conformers (see Table   below ) were found for the fenamates in the range of 10 kcal/mol. Results were similar to the ones previously reported (Dhanaraj and Vijayan, 1988) . 3-phenyl-CPP, a more flexible molecule, showed a larger number of conformers (see Table 1 ) in the same range of energy. For FFA, MCFA, NFA and 3-phenyl-CPP the same conformational analysis was carried out also in the presence of water and results were close to those without solvent.
In Table 1 , we report the number of low energy conformers found after the conformational analysis carried out with and without water.
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When available, as in the case of DPC, FFA, MCFA, MFA, NFA and TFA molecules, the starting geometry parameters were derived from X-ray data from CCDC (Cambridge Crystallographic Data Center) (Cambridge Structural Database V5.26, Nov. 2004 , upd. Feb. 2005 .
For 3-phenyl-CPP, whose X-ray data were not available, the molecule was first constructed by fragments, the molecular geometry was optimized to DFT B3LYP/6-31G* level theory and then submitted for further calculations (Spartan '04 Wavefunction, Inc. Irvine, CA.). Except for molecular mechanics and semi-empirical models, the calculation methods used in Spartan'04 have been documented in (Kong et al., 2000) . We observed that the most populated low energy conformer families are within the 3.0 kcal/mol range; among them the lowest energy conformer was selected and used for the overlay show in Fig. 9B . The conformers were superimposed at the level of the aromatic ring not directly bound to the carboxylic group, and of the heteroatoms, nitrogen or oxygen, bridging the aromatic rings.
All calculations were performed with the SPARTAN '04 package (Wavefunction Inc., Irvine, CA).
Graphical representations were performed by DS Viewerpro 6.0 trial version (Accelrys Inc., San Diego, CA).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effect of fenamates on CLC-Ka
Effect of NFA
In the first series of experiments we characterized the effect of NFA on the CLC-Ka channel. CLCKa currents partially deactivate at positive potential and activate at negative potentials (Fig. 1A left).
Application of 200 µM NFA induces an increase of CLC-Ka currents both at negative and positive potentials (Fig. 1A) . The on-set of the effect was rapid while the return of the currents to control value upon removal of drug was reached within 7-9 minutes (Fig. 1B) . The NFA-mediated current increase was practically voltage independent (I drug /I 0 = 2.38 ± 0.12 at 60 mV and I drug /I 0 = 2.20 ± 0.3 at -140 mV). At all tested potentials, NFA induced an increase of the current amplitude without producing kinetic modifications. While a current increase was seen for concentrations between 50
and 1000 µM, NFA blocked CLC-Ka currents at 2 and 2.5 mM (Fig. 1C ). This biphasic doseresponse relationship indicates that the mechanism of action of NFA is complex, likely involving two functionally different binding sites with opposite effects.
Dependence of NFA activation on extracellular calcium concentration
It is known that CLC-K channel activity is strongly enhanced by extracellular calcium in the millimolar range (Estévez et al., 2001; Waldegger et al., 2002) . We examined whether calcium may interfere with the activating effect of NFA. Lowering [Ca 2+ ] ext from 10 mM to 1.8 mM reduces CLC-Ka currents (data not shown), and, importantly, the relative activating effect of 200 µM NFA was significantly larger in low calcium (Fig. 2) . A possible interpretation of increased potency of NFA in low calcium is that in this condition a larger population of channels is available for opening by NFA.
Structure-activity study
Searching to determine the structural requisites to bind to and to modulate CLC-Ka activity, we evaluated the effect of a series of compounds, modifying in different parts the NFA structure (Fig.   3 ). We determined the potency of the various derivatives by comparing the effect produced by each drug at 200 µM, a concentration at which the NFA-mediated activating effect was evident.
Substitutions on the phenyl group. Derivative MT-7 in which the CF 3 group on the phenyl ring is shifted from the meta to the para position with respect to the anilinic nitrogen is still able to produce an increase of CLC-Ka currents, albeit with a reduced potency (ratio I drug /I 0 of 1.89 ± 0.04; Fig. 4A ).
Much more drastic in compromising the activating drug activity resulted the substitution of the CF 3 group with a chlorine atom. Indeed, application of derivatives MT-6 and MT-4 having a chlorine atom in meta or in para position, respectively, only slightly increased or did not produce any effect, respectively ( Fig. 4A ). These data indicate that an electronegative effect that reduces the density of the electron cloud of this aromatic ring is not sufficient to confer drug activity. Rather, the presence of the threefluoromethyl group seems to confer a specific bulkiness in this part of the molecule suitable for the interaction with the activating binding site. the formal possibility that the lack of effect of substances Li-15, Li-3, Li-10, Li-6 and Li-11 was due to a compensation of activation and block we evaluated them also at 50 µM. If at 200 µM block would have masked an activating effect, at the lower concentration of 50 µM an increase of currents would be expected. However, also at this concentration, none of these derivatives produced a significant effect (data not shown).
Elimination
Conversion of the pyridinic ring into a phenyl ring.
In FFA, the pyridinic ring is substituted with a phenyl one ( Table 2 ). The elimination of all substituents on this phenyl group (molecule DPC, Fig.3 ) significantly reduced the drug inhibitory activity (Fig. 5A , Table 2 ).
These results suggest that the substitution of the pyridinic group with a phenyl one completely shifted the affinity of NFA from an activating binding site to an inhibitory binding site with some different structural requirements.
We also evaluated the effect of 3-phenyl-CPP, the CLC-K blocker with highest affinity known up to now (Liantonio et al., 2004; Picollo et al., 2004) . In agreement with a previous study (Picollo et al., 2004 ), 3-phenyl-CPP inhibited CLC-Ka currents with a potency reported in Table 2 .
Effect of fenamates on CLC-Kb
This article has not been copyedited and formatted. The final version may differ from this version. Although highly homologous (Kieferle et al., 1994) , the two CLC-K isoforms show a different pharmacological profile (Picollo et al., 2004) . We evaluated the sensitivity of CLC-Kb to fenamates using NFA and FFA, the two lead compounds with activating and inhibitory effect on CLC-Ka. At 200 µM, the effect of NFA on CLC-Kb is more pronounced compared to CLC-Ka, with a ratio I drug /I 0 of 3.5 ± 1.0.
Interestingly, in contrast to what observed on CLC-Ka, also application of 200 µM FFA produced an increase of CLC-Kb currents with a ratio I drug /I 0 of 2.09 ± 0.9 at 60 mV (Fig. 7) . Furthermore, NFA even at high concentrations (> 1 mM) was incapable of blocking CLC-Kb sustained currents, producing at all tested concentrations a potentiation (data not shown).
Effect of NFA and FFA on CLC-K mutants
We have previously identified N68 on CLC-Ka as a key amino acid of the binding site for 3- To asses this hypothesis we tested FFA and its derivatives on the CLC-Ka mutant N68D, the mutant that was least sensitive to 3-phenyl-CPP block (Picollo et al., 2004) . 200 µM FFA did not produce any significant decrease of currents sustained by CLC-Ka N68D, suggesting that this point mutation strongly reduced drug affinity. MCFA, the most potent derivative among the here tested compounds on CLC-Ka, showed a K D of 632 ± 101 µM, an almost 15-fold decrease in affinity compared to WT. For all other FFA derivatives the apparent K D value was > 1 mM (Table   2) .
We next tested NFA on all mutants previously reported both for CLC-Ka and CLC-Kb (Picollo et al., 2004) . Each mutant resulted sensitive to NFA with a potency comparable to that observed in the related wild type (Fig. 8) . However, it is interesting to notice that NFA produced a slightly smaller This article has not been copyedited and formatted. The final version may differ from this version. effect on CLC-Ka N68D with respect to WT (Fig. 8) , indicating that the activating and inhibitory binding site may not be completely independent.
At high concentrations such as 2 mM, NFA is still capable of producing a block of CLC-Ka N68D mutant although less potently with respect to CLC-Ka wild type (I drug /I 0 = 0.75 ± 0.05 and I drug /I 0 = 0.67± 0.04 at 60 mV, respectively).
Modeling study
Conformational search studies show that all examined NFA derivatives exhibit a restricted number of low energy conformers characterized by the presence of an intramolecular hydrogen bond between the amino group and the oxygen atoms of carboxylic moiety. For all examined molecules, the calculated low energy conformations include the ones found in the X-ray crystal structures.
The lowest energy conformer of NFA shows a quite planar structure, differently from the corresponding conformers of the remaining molecules in which the two aromatic rings lie on different planes (Fig. 9A) . The NFA planar structure is the result of the intramolecular hydrogen bonding as well as of the conjugation of the amino group lone-pair with the electron withdrawing pyridine ring. This conjugation is less effective in the FFA analogs due to the substitution of the pyridine system with a phenyl; at the same time, this substitution introduces an additional hydrogen atom in ortho position to the amino group causing a steric hindrance in the resulting diphenyl system which forces the non co-planar arrangement of the aromatic rings (Dhanaraj and Vijayan, 1988 ). This behavior is enhanced in the compounds having bulky substituents in the ortho positions of the aniline moiety such as MCFA, MFA and TFA (Fig. 9A) .
Regarding 3-phenyl-CPP all lower energy conformer families exhibit the two aromatic rings lying on different planes due to their molecular flexibility.
An overlay of the lowest energy conformers of the lead molecules, indicates that all blocking compounds such as FFA and 3-phenyl-CPP displayed non-planar geometries in contrast to NFA (Fig.9B ).
Discussion
In the present work we demonstrated that in addition to a blocking site (Picollo et al., 2004) , CLC-K chloride channels have also an activating binding site. In dependence on the chemical structure fenamates are capable of blocking or opening CLC-Ka. NFA is able to increase CLC-Ka currents at all tested membrane potentials in the 10-1000 µM range with a rapid on-set and a relative slow, but complete, recovery suggesting binding to a site that is accessible from the extracellular side. The activating effect was markedly increased when the extracellular calcium concentration was lowered.
The opposite charge carried by NFA and calcium ions leads us to exclude a possible competition between these CLC-Ka activators for a common binding site. Thus, the increased potency of NFA in low calcium is probably simply due to the fact that in this experimental condition, more channels are available for NFA activity.
Starting from NFA as the lead compound, and considering all double-ring compounds shown in Fig. 3 the following structural requisites for an efficient activation of CLC-Ka emerged: the acidic carboxylic group, two aromatic rings one of which preferentially a pyridinic ring, a CF 3 group in meta position on the phenyl group, an anilinic moiety connecting the two rings. Several of these requisites are shared to enable efficient blocking activity. These include the carboxylic group and the two aromatic moieties linked by an electronegative atom. All FFA derivatives produced a rapid and reversible block with a mechanism of action resembling that of 3-phenyl-CPP. Interestingly, the presence of these groups is pivotal for blocking activity also in the 3-phenyl-CPP structure. can not be excluded that also at low concentration a certain drug amount binds the inhibitory binding site. In support of this, the activating effect of 200 µM NFA was more evident on CLC-Kb, the CLC-K isoform that is much less sensitive to blockers (Picollo et al., 2004) . In parallel, the presence of two phenyl groups, as occurs in FFA derivatives, confers a larger affinity toward the inhibitory binding site on CLC-Ka. However, also in this case it seems that the same molecules are also capable of interacting with the activating binding site as evidenced by the FFA-induced increase of CLC-Kb currents.
In a previous study, we mapped the binding site of 3-phenyl-CPP and DIDS on CLC-Ka, pinpointing the neutral amino acid N68 as crucial for 3-phenyl-CPP-mediated inhibition since mutating it to the negatively charged aspartate (N68D), as occurs in CLC-Kb, markedly reduced drug sensitivity (Picollo et al., 2004) . All FFA derivatives resulted much less potent in blocking CLC-Ka N68D mutant with respect to CLC-Ka wild type, indicating that N68 is pivotal for drug blocking activity. Furthermore, we showed that FFA loses its blocking activity on CLC-Kb, respectively. However, it should be kept in mind that, as we hypothesized for the inhibitory binding site (Picollo et al., 2004) , the effective activating binding site could be quite deep within the pore.
Thus, it should not be excluded that the two binding site are partially overlapping. The precise identification of the activator site on CLC-K channels will be needed to conclusively resolve this issue.
We attempted to explain the different drug activity by performing modeling investigations that allow us to compare the spatial geometry profiles associated at NFA, FFA and 3-phenyl-CPP structures. The most important conclusion is that NFA and its analogues MT-4 and MT-7 that behave as CLC-Ka openers show nearly planar conformations, while FFA derivatives and 3-phenyl-CPP, exhibiting a CLC-Ka blocking activity, are forced to assume a non co-planar arrangement of the aromatic rings. Overlaying the lowest energy conformers reveals that all blocking compounds display non-planar geometries compared to NFA and that the increasing planarity distortion of the aromatic rings ranging from DPC, FFA, MFA, TFA to MCFA parallels the observed increasing blocking activity in the same order.
The involvement of CLC-Kb in type III Bartter' syndrome and the parallel lack of drug treatment arouse a great interest toward molecules able to open CLC-K channels. The use of a compound similar to NFA for a treatment of Bartter's syndrome could improve diuresis in a direct manner through an increase of CLC-K channel activity and in an indirect manner through cyclooxygenase inhibition. Indeed type III Bartter's syndrome patients show an elevated prostaglandin activity This article has not been copyedited and formatted. The final version may differ from this version. (Reinalter et al., 2002) and NFA belongs to the class of non-steroidal anti-inflammatory drugs.
However, the activating effect of NFA on mutants of CLC-Kb has not been tested in the current study.
At the same time, considering the involvement of CLC-K channels in the mechanisms of urine concentration, specific inhibitors could represent a new class of drugs with diuretic activity (Fong, 2004) . At this regard it is worth to notice that whereas CLC-K2/Kb is clearly restricted to basolateral membranes of renal epithelial cells, the localization of CLC-K1/Ka is still controversial.
Both basolateral and apical membranes (Uchida et al., 1995) Besides, recently a polymorphism of CLC-Kb was reported (T481S) that, in contrast to mutations responsible of Bartter's syndrome, confers a gain of function. Indeed, T481S mutant channels led to a dramatic increase in CLC-Kb currents when expressed in oocytes (Jeck et al., 2004a) . This polymorphism was associated with hypertension in one study (Jeck et al., 2004b) . However, an involvement of this polymorphism was not seen in other studies (Speirs et al., 2005; Kokubo et al., 2005) . Thus, a specific inhibition of CLC-K channels as a treatment of such a condition, remains speculative. Although the CLC-K inhibitors identified up to now showed a major affinity toward the CLC-Ka isoform, they represent drugs with good therapeutic potential, permitting a reduction of CLC-Ka activity for counteracting the excessive CLC-Kb activity.
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